Patient monitoring failure lawsuits arise when healthcare facilities or medical device manufacturers fail to properly observe, track, or respond to critical patient data, resulting in preventable harm or death. These cases challenge the fundamental duty of hospitals, physicians, and device makers to continuously monitor patient conditions and intervene when warning signs appear. The consequences can be catastrophic. In March 2026, the family of Conor Hylton, a 26-year-old dental student from Connecticut, filed a wrongful death lawsuit after he died in the intensive care unit of Bridgeport Hospital’s Milford campus. Despite spending over four hours in the ICU, Hylton never received an in-person evaluation from a physician.
Instead, a remote tele-ICU provider monitored him through a video screen, ultimately pronouncing him dead via that same screen rather than in person. Hylton had been admitted for alcohol-induced pancreatitis with severe metabolic complications and was intubated during his ICU stay, but the hospital’s reliance on remote monitoring meant critical warning signs went unrecognized by a physically present clinician. Patient monitoring failures span both clinical settings and medical devices. The FDA’s Class I recall of Abbott’s FreeStyle Libre 3 glucose monitors reveals the scope of this problem beyond hospital walls. As of November 2025, 736 serious injuries had been reported associated with these continuous glucose monitors, and 7 deaths were linked to inaccurate glucose readings. When monitoring systems—whether a physician, a nurse, or a device—fail to function properly or are understaffed, patients with serious conditions like diabetic emergencies or acute pancreatitis face life-threatening delays in treatment.
Table of Contents
- What Constitutes a Patient Monitoring Failure in Lawsuits?
- The Rise of Tele-ICU Monitoring and Its Risks
- Medical Device Monitoring Failures and Glucose Monitoring Litigation
- Legal Standards and Burden of Proof in Monitoring Failure Cases
- Common Issues in Patient Monitoring Litigation
- Regulatory Action and the Role of Public Health Investigations
- The Future of Patient Monitoring Standards
- Conclusion
What Constitutes a Patient Monitoring Failure in Lawsuits?
A patient monitoring failure lawsuit holds healthcare providers or device manufacturers legally responsible when their failure to adequately observe patient status directly causes injury or death. This is distinct from a simple medical error or bad outcome; it specifically involves a breach of the duty to monitor. In Hylton’s case, the lawsuit centers on the hospital‘s decision to rely exclusively on a remote tele-ICU provider for a critically ill patient requiring intensive observation. Connecticut’s Department of Public Health investigation, completed in July 2025, concluded that the hospital failed to ensure appropriate medical care. The allegation is stark: a patient admitted to an intensive care unit—the highest level of in-hospital monitoring—received no in-person physician assessment during his 18-hour stay and 2 hours following intubation.
The defendants, Yale New Haven Health and Northeast Medical Group, face claims that this monitoring gap violated the patient’s right to proper critical care. Medical device monitoring failures operate under similar legal principles but with different defendants. The FreeStyle Libre 3 recall involves Abbott as the manufacturer rather than a hospital system. When a device continuously measures blood glucose but reports inaccurate readings, diabetic patients may miss dangerous highs (hyperglycemia leading to diabetic ketoacidosis) or lows (hypoglycemia leading to seizures, coma, or death). The device itself is the monitoring system, and if it fails to accurately track patient status, it has failed its core purpose. Unlike a healthcare provider who might be temporarily unavailable, a faulty sensor cannot be trusted at any moment, making the monitoring failure systemic rather than situational.
The Rise of Tele-ICU Monitoring and Its Risks
Tele-ICU programs position remote physicians to monitor multiple patients across different hospitals, reducing labor costs and providing expertise to smaller facilities. However, this model introduces risks that traditional in-person ICU care does not carry. A remote physician cannot perform a physical examination, cannot assess changes in patient appearance or responsiveness that might not be captured by monitors, and cannot immediately respond to sudden deterioration. In Hylton’s case, the tele-ICU provider was monitoring via video screen—a medium that fundamentally constrains clinical assessment. Even if monitors showed declining vitals, the remote physician could not lay hands on the patient, adjust equipment directly, or immediately call a code if the situation deteriorated faster than anticipated. The legal question becomes whether the hospital was negligent in choosing a tele-ICU model for a critically ill patient, particularly one who should have been under continuous supervision.
The limitation of tele-ICU monitoring is most apparent in acute situations. A patient with pancreatitis and metabolic acidosis faces rapid changes in condition. Physical signs—skin color, capillary refill, level of consciousness—provide critical context that no monitor can fully capture. When a tele-ICU provider spotted something alarming, there was a built-in delay: the remote physician had to communicate with bedside staff who then took action. In traditional ICU care, the physician is present and can immediately intervene. This structural difference has profound implications for litigation, especially when the patient dies within 18 hours of admission. Families can argue that had a competent in-person physician been present throughout the stay, the outcome might have been different.
Medical Device Monitoring Failures and Glucose Monitoring Litigation
The FreeStyle Libre 3 glucose monitor cases represent a different category of patient monitoring failure: a device designed to continuously track glucose levels but failing to do so accurately. These sensors are not backup monitoring systems—for many diabetic patients, they are the primary tool for day-to-day glucose management. When 736 injuries and 7 deaths have been reported in connection with a single device, and the FDA has issued a Class I recall, the pattern suggests the monitoring system itself is fundamentally unreliable. Patients and families are arguing that Abbott failed to ensure the device accurately reported glucose levels, leading to missed warnings of dangerous swings. The specific harm differs from the Hylton case but reflects the same core problem: a patient monitoring system failed. In Conor Hylton’s situation, the monitoring failure was organizational and staffing-based.
In FreeStyle Libre 3 cases, the failure is technological. A diabetic patient might believe their glucose is under control based on the sensor reading, when in fact their blood sugar is dangerously high or low. Unlike Hylton, who was in a hospital where other monitoring systems existed, diabetic patients using these sensors may be unaware they are receiving false data. The device’s inaccuracy becomes the monitoring failure. As of November 2025, no major settlements have been publicly announced in the FreeStyle Libre 3 cases, though the first class action was filed in January 2026 in California. Some sources reference a potential settlement range of up to $7.25 billion, though this remains unconfirmed.
Legal Standards and Burden of Proof in Monitoring Failure Cases
Proving a monitoring failure lawsuit requires establishing that the healthcare provider or device manufacturer had a duty to monitor, that they breached that duty, that the breach directly caused harm, and that damages resulted. In hospital cases like Hylton’s, the duty to monitor is clear: ICU patients have a legal right to continuous observation and appropriate care. The breach is documented by the investigation finding that the hospital failed to ensure appropriate care. The causation argument becomes central: could the patient have survived with proper monitoring? Medical experts will need to testify that a competent in-person ICU physician would have recognized warning signs and intervened differently.
One significant limitation in these cases is that proximate cause can be difficult to prove. A patient might claim that had they known their glucose reading was inaccurate, they would not have eaten certain foods or would have checked their blood sugar manually. But showing that manual check would have happened, or that the patient would have acted on more accurate information, requires assumption about patient behavior. Similarly, in Hylton’s case, proving that an in-person physician would have changed the outcome requires showing what that physician would have done differently and that intervention would have prevented death. This is why expert medical testimony is so critical in these cases.
Common Issues in Patient Monitoring Litigation
One recurring issue in monitoring failure cases is inadequate staffing. Hospitals sometimes argue that staff shortages, while problematic, do not constitute actionable negligence if protocols were followed. However, if a hospital cannot staffing an ICU adequately and instead relies on remote monitoring for critically ill patients, the question becomes whether the system itself is negligent. The Hylton case will likely explore whether Bridgeport Hospital’s reliance on tele-ICU for his level of acuity was reasonable under any circumstances. Another common limitation is the “eggshell plaintiff” defense.
Defendants may argue that even with perfect monitoring, the patient’s underlying condition was so severe that death was inevitable. Hylton had acute pancreatitis with metabolic acidosis and dehydration—conditions with high mortality rates even in optimally managed cases. Defendants will argue that nothing a bedside physician could have done would have changed his outcome. Plaintiffs counter that we will never know what a competent in-person physician might have recognized and attempted. This clash is inherent to monitoring failure cases: the monitoring failure is proven, but whether it caused the specific outcome remains contested.
Regulatory Action and the Role of Public Health Investigations
The Connecticut Department of Public Health investigation into Conor Hylton’s death strengthens the lawsuit. Regulatory investigations that find violations provide evidence that a standard of care was breached. The investigation’s conclusion that the hospital failed to ensure appropriate care is powerful testimony that the hospital’s actions fell below accepted standards. In contrast, medical device cases like the FreeStyle Libre 3 litigation are driven partly by FDA involvement.
The Class I recall—the highest level of FDA recall—signals that the agency believes the device poses a serious risk of injury or death. This regulatory determination is compelling evidence of a monitoring failure, as it indicates the device cannot be relied upon to accurately track patient status. PUBLIC HEALTH INVESTIGATIONS: These reviews, while not binding in court, establish an independent finding that care standards were not met. A plaintiff’s attorney can present the investigation’s conclusions to argue the defendant’s negligence. However, there is a distinction between a public health finding that care was inadequate and a court determination that this inadequacy caused the death.
The Future of Patient Monitoring Standards
The Hylton case will likely influence how hospitals approach tele-ICU implementation for critically ill patients. If the lawsuit succeeds, it signals that tele-ICU cannot be a substitute for in-person care in all situations, particularly for patients with acute, rapidly changing conditions. Healthcare systems may need to establish guidelines specifying which patients require bedside physician presence and which can be safely monitored remotely. The FreeStyle Libre 3 litigation highlights the need for stronger post-market surveillance of medical devices.
Manufacturers must detect safety issues earlier and communicate them to patients. Future glucose monitoring devices will face greater scrutiny and testing requirements. For patients currently using these or similar devices, regulatory warnings and recalls are the primary mechanism for learning that monitoring data may be unreliable—a reactive rather than proactive approach. As more patient monitoring shifts to devices and remote systems, the legal and regulatory framework will likely tighten to ensure these systems maintain the same standard of care that in-person observation once provided.
Conclusion
Patient monitoring failure lawsuits hold healthcare systems and device manufacturers accountable when they fail to properly observe patients or track critical health data. The Conor Hylton wrongful death case illustrates how over-reliance on remote monitoring in an intensive care setting can breach the duty of care when a critically ill patient receives no in-person physician evaluation. Similarly, the FreeStyle Libre 3 glucose monitor recall and ensuing litigation demonstrate that monitoring failures extend beyond hospital walls to devices patients depend on for day-to-day health management.
These cases are significant because they address a growing trend: the shift toward remote and device-based monitoring as a cost-saving measure. The legal system will increasingly grapple with questions about whether such systems can meet the standard of care required in critical situations. For patients and families who have suffered harm due to monitoring failures, litigation offers a mechanism to hold responsible parties accountable and to create pressure for systemic improvements in how monitoring systems are designed, implemented, and supervised.